Kelvin K.H. Bao, Carol HY Wong, Jackie Yung, Venus Tam, Ka Man Cheung, Jeffrey C H. Chan. "Should CDK4/6 inhibitor plus endocrine therapy be standard of care for ER-low (1–10%) HR+/HER2− metastatic breast cancer? A multicenter registry cohort.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1102